RedHill Biopharma Ltd. Appoints Key Opinion Leader Professor Colm O'Morain, President of The United European Gastroenterology Federation (UEGF) as Lead Investigator for the European Pivotal Clinical Trial with RedHill 's Crohn’s Drug – RHB-104

TEL AVIV, Israel--(BUSINESS WIRE)--RedHill Biopharma Ltd. (TASE: RDHL), an emerging Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical-stage patented new formulations and combinations of existing drugs, announced the appointment of Professor Colm O'Morain, MD, as the lead investigator of the Company's planned pivotal European clinical trial with RHB-104, its proprietary therapy for Crohn's disease. In this role, Prof. O'Morain has broad responsibilities in the design of the clinical trial and will be actively involved in its execution and in the publication of its results.